Diurnal blood pressure profile and coronary atherosclerosis extent are related to cardiovascular complications

Figures & data

Table 1. Baseline characteristics of the study group.

	Total group	Without CAS	1 or 2 CAS	≥ 3 CAS
	(n = 1345)	(n = 454)	(n = 563)	(n = 328)
Male	820 (60.7)	206 (45.4)	369 (65.5)^†	241 (73.5)^†
Age (years)	63.2 ± 9.2	62.5 ± 9.0	64.7 ± 9.2	65.1 ± 9.3^†
Diabetes	279 (21)	78 (17.2)	139 (24.7)^†	78 (23.8)^†
Smokers	208 (15)	51 (11.2)	103 (18.3)^†	50 (15.2)^†
Total cholesterol (mg/dl)	205.2 ± 52.2	203.0 ± 48.7	206.7 ± 56.0	205.5 ± 52.6
LDL-cholesterol (mg/dl)	120.5 ± 43.0	117.7 ± 40.8	122.1 ± 43.9	121.7 ± 44.4
HDL-cholesterol (mg/dl)	55.3 ± 13.6	58.4 ± 14.3	54.5 ± 13.8^†	52.5 ± 11.5^†
Triglycerides (mg/dl)	147.6 ± 99.5	138.2 ± 91.6	152.5 ± 108.2^†	152.1 ± 93.3^†
Medications
ASA	1013 (75.3)	208 (45.8)	505 (89.7)^†	300 (91.5)^†
Lipid-lowering drugs	1217 (90.5)	392 (86.3)	520 (92.4)	305 (93.0)
β-Blockers	1077 (80.1)	353 (77.7)	451 (80.1)	273 (83.2)
Calcium channel blockers	309 (23.0)	118 (26.0)	135 (24.0)	56 (17.1)
ACE inhibitors/ARB	998 (74.2)	279 (61.4)	436 (77.4)	258 (78.6)
Diuretics	147 (10.9)	46 (10.1)	66 (11.7)	35 (10.7)

Data are shown as mean ± SD or n (%).

CAS: significant coronary artery stenosis; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ASA: acetylsalicylic acid; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker.

*p < 0.03 vs without CAS;

† p < 0.001 vs without CAS.

Figure 1. Diurnal systolic blood pressure (SBP) variability. †p < 0.01: group with one or two significant coronary artery stenoses (CAS) vs without CAS; ‡p < 0.02: group with three or more CAS vs group without CAS.

Figure 2. Diurnal diastolic blood pressure (DBP) variability. †p < 0.01: group with one or two significant coronary artery stenoses (CAS) vs without CAS; ‡p < 0.02: group with three or more CAS vs group without CAS; #p < 0.05: group with one or two CAS vs group with three or more CAS.